Table 1 Basic characteristics of 134 non-small cell lung cancer patients with brain metastases
Characteristics | All (N = 134) | Gefitinib (N = 62) | Erlotinib (N = 49) | Afatinib (N = 23) | p value |
|---|---|---|---|---|---|
Age > 65 years old | 61 (45.5%) | 29 (46.8%) (38–93 yr) | 26 (53.1%) (41–86 yr) | 6 (26.1%) (42–81 yr) | .097 |
Male sex | 38 (28.4%) | 17 (27.4%) | 13 (26.5%) | 8 (34.8%) | .750 |
Smoking | 16 (11.9%) | 8 (12.9%) | 4 (8.2%) | 4 (17.4%) | .504 |
EGFR mutation status | .046 | ||||
 L858R | 56 (41.8%) | 26 (41.9%) | 26 (53.1%) | 4 (17.4%) |  |
 Del 19 | 69 (51.5%) | 31 (50.0%) | 21 (42.9%) | 17 (74.0%) |  |
 Uncommon mutation | 5 (3.7%) | 3 (4.8%) | 2 (4.1%) | 0 |  |
 Complex mutations | 4 (3.0%) | 2 (3.2%) | 0 | 2 (8.7%) |  |
Initial brain metastases number ≥ 3 | 88 (65.7%) | 33 (53.2%) | 33 (67.3%) | 15 (65.2%) | .527 |
Other metastastic location | |||||
 Lung | 54 (40.3%) | 24 (38.7%) | 21 (42.9%) | 9 (39.1%) | .900 |
 Bone | 87 (64.9%) | 42 (67.7%) | 32 (65.3%) | 13 (56.5%) | .627 |
 Liver | 26 (19.4%) | 8 (12.9%) | 12 (24.5%) | 6 (26.1%) | .208 |
 Pleura | 35 (26.1%) | 21 (33.9%) | 8 (16.3%) | 6 (26.1%) | .113 |
 Other location | 23 (17.2%) | 5 (8.1%) | 12 (24.5%) | 6 (26.1%) | .034 |
M1c (definition by AJCC 8th edition) | 123 (91.8%) | 56 (90.3%) | 48 (98.0%) | 19 (82.6%) | .073 |
Radiotherapy to brain metastases | 38 (29.1%) | 24 (38.7%) | 13 (26.5%) | 2 (8.7%) | .018 |
Brain tumor excision | 8 (6.0%) | 7 (11.3%) | 1 (2.0%) | 0 | .052 |